How the PlasmoSniff test works and its impact on diagnosis

Engineers at the Massachusetts Institute of Technology (MIT) have developed an innovative breath test called 'PlasmoSniff', which allows for the diagnosis of pneumonia in just a few minutes, without the need for complex X-rays or laboratory tests. The technology uses a portable sensor capable of detecting disease biomarkers in the patient's exhaled air. The patient inhales specially designed nanoparticles that carry synthetic biomarkers. In the presence of pneumonia, the infection's enzymes separate the biomarkers from the particles, and they are exhaled and detected by the sensor. The device uses plasmonics to capture the molecules, analyzing them through Raman spectroscopy. The test has been validated on lung fluid samples from mice, demonstrating the ability to detect signals at extremely low concentrations. Researchers are working on integrating the system into a portable device, which could also be used for other diseases, including cancer or viral infections. The PlasmoSniff technology promises to make the diagnosis of lung diseases faster and more accessible globally.